This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland
Menu

Antti Vuolanto
Chief Executive Officer at Herantis Pharma plc
Speaker

Profile

Antti Vuolanto, DSc (Tech), CEO or Herantis Pharma plc started in his current role in July 2022. He joined Herantis in February 2018 as COO. Antti has vast experience in financing, partnering, research, development, and manufacturing of biological drugs. Previously he served as COO at Valo Therapeutics, Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that merged with Targovax in 2015. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.

Agenda Sessions

  • Development of HER-096 as a Disease Modifying Therapy for Parkinson’s Disease

    , 10:15
    View Session

At this event

Prev
Next
Dr. Zhong Wang, PhD
Founder & CTO
Allbiosyn Biotechnology Co., Ltd.

See Antti at TIDES Europe: Oligonucleotide and Peptide Therapeutics